Back to Directory
Ulimorelin
Performance & EnduranceGhrelin receptor agonist for postoperative ileus and GI dysmotility.
Key Benefits
- ✓Accelerates GI recovery post-surgery
- ✓Treats gastroparesis
- ✓Promotes GI motility
- ✓Reduces postoperative ileus
Dosing Information
Dosage Range
Research stage
Frequency
Development discontinued
Typical Duration
N/A
Detailed Protocol
Development discontinued. Was studied as IV infusion in postoperative setting.
About Ulimorelin
Ulimorelin (TZP-101) is a synthetic ghrelin receptor agonist developed for gastroparesis and postoperative ileus. It accelerates GI recovery after surgery. Clinical development appears discontinued despite positive phase 2 results.
Research Notes
Phase 2 trials showed efficacy for postoperative ileus but development discontinued. Demonstrated ghrelin agonist effects on GI motility.
Potential Side Effects
- •Development discontinued
- •Generally well tolerated in trials
Always consult with a healthcare professional before starting any peptide therapy.